BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 12, 2016
View Archived Issues
Japan Tobacco, Torii and Menlo enter serlopitant license agreement
Read More
KalVista initiates first-in-human trial of KVD-818 for the treatment of hereditary angioedema
Read More
Vedanta and NYU Langone to develop microbiome-derived immunotherapies for cancer
Read More
Targeting the parasite proteosome shows promise for the treatment of kinetoplastid infections
Read More
Ascendis initiates phase III registration trial for TransCon growth hormone
Read More
Bayer Pharma patents mitotic checkpoint serine/threonine-protein kinase BUB1 inhibitors
Read More
Polyphor and Gilead enter macrocycle drug discovery collaboration
Read More
Novogen submits IND to FDA for cantrixil
Read More
VAL-401 receives regulatory approval for phase IIb clinical trial in Georgia
Read More
Resverlogix will continue phase III trial testing apabetalone based on DSMB recommendation
Read More
Medshine Discovery discloses JAK inhibitors
Read More
MedImmune develops TB4 fusion polypeptides
Read More
Mallinckrodt to acquire Stratatech Corporation
Read More
Wockhardt reports beta-lactamase inhibitors
Read More
Inovio Pharmaceuticals doubles enrollment for its phase I trial of Ebola vaccine
Read More
Zealand Pharma reports results from phase II trial of dasiglucagon
Read More
Acacia Pharma announces pivotal phase III results of Baremsis for the treatment of PONV
Read More
Zymeworks begins research collaboration with Innovative Targeting Solutions
Read More
Targeting astroglial NF-kappaB signaling as a novel treatment option for vascular dementia
Read More
BioCryst Pharmaceuticals doses first subject in phase II trial of BCX-7353
Read More
Epizyme doses first patient in phase II trial of tazemetostat
Read More
Pfizer reveals milestones of second quarter 2016
Read More
Advaxis advances phase II trial of axalimogene filolisbac to its second stage
Read More
Cryoport expands contract with Stemedica for stem cell therapies against Alzheimer's disease
Read More
Vigilant Biosciences receives phase I grant for next-generation oral cancer diagnostic test
Read More
EZH1 mutations are the second most frequent genetic alteration in ATAs
Read More